Ironwood Pharmaceuticals Inc. Class A (IRWD)
NASDAQ: IRWDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IRWD stock chart
Technical analysisKey statistics
All statistics- Market cap
- $778.09M
- P/E (TTM)
- 5.22
- Forward P/E
- 3.00
- EPS (TTM)
- $0.90
- Dividend yield
- None
- 52-week range
- 2.95 – 5.78
- Day range
- 4.65 – 4.87
- Volume / Avg
- 3.02M / 2.15M
- Beta
- —
- Shares outstanding
- 165.55M
52-week range
IRWD stock today
Ironwood Pharmaceuticals (IRWD) closed at $4.70 on Nov 20, down 0.21% (-$0.01), versus the S&P 500's 3.70% decline. At this level, IRWD sits in the middle of its 52-week range of $2.95 to $5.78: 18.7% below the high, set on Jan 2, 2026 and 59.3% above the low. IRWD is up 39.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 48.7%.
Ironwood Pharmaceuticals trades at 5.2x its trailing twelve-month earnings per share of $0.90. Its forward P/E of 3.0x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Ironwood Pharmaceuticals
Company profileIronwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Thomas A. McCourt
- Headquarters
- Boston, MA
- Employees
- 100
- IPO year
- 2010
- Website
- ironwoodpharma.com
Financial highlights
Full financialsIn fiscal 2025, Ironwood Pharmaceuticals generated $296.2 million in revenue, down 15.7% from fiscal 2024, its first annual decline since 2024. Net income was $24.0 million (+2629.2% year over year), for a net margin of 8.1% versus a median of 27.3% in the prior 5 years. Operating margin was 33.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $296.15M | $351.41M | $442.74M | $410.60M | $413.75M |
| Growth | -15.72% | -20.63% | +7.83% | -0.76% | +6.22% |
| Net income | $24.02M | $880.00K | $-1.00B | $175.06M | $528.45M |
| EPS (diluted) | $0.15 | $0.01 | $-6.45 | $0.96 | $3.21 |
Analyst forecast
ForecastConsensus (4 analysts)
buy
Avg. price target
$6.18+31.49%
- Strong buy 1
- Buy 1
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $0.36 vs $0.30
- Surprise
- +20.00%
IRWD news
All IRWD news- IRWD Q3 Earnings Beat, Revenues Miss, 2026 View Raised, Stock UpNasdaqIRWD, AZN, ABBV, COLL
- Ironwood (IRWD) Q3 2026 Earnings Call TranscriptNasdaq
- What Ironwood Pharmaceuticals (IRWD) Said on Its Q3 Earnings CallNasdaq
- Ironwood Pharmaceuticals Raises Full-Year 2026 Financial Guidance Driven by Continued LINZESS U.S. Net Sales Growth and Strong Third Quarter Financial PerformanceBusiness Wire
- Ironwood Pharmaceuticals Q3 2026 Earnings PreviewSeeking Alpha
- Why is Ironwood Pharmaceuticals stock sliding today?Investing.com
- Ironwood Pharmaceuticals stock falls on CEO transition newsInvesting.com
- Ironwood Pharmaceuticals names Tammi Gaskins CEOSeeking Alpha
Ironwood Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SNDXSyndax Pharmaceuticals Inc. | 8.72 | -4.49% | $785.05M | vs IRWD |
| COLLCollegium Pharmaceutical Inc. | 24.72 | -1.94% | $768.18M | vs IRWD |
| ORICOric Pharmaceuticals Inc. | 7.36 | -4.42% | $764.94M | vs IRWD |
| VSTMVerastem Inc. | 6.33 | -7.73% | $797.67M | vs IRWD |
| RIGLRigel Pharmaceuticals Inc. | 40.09 | -2.67% | $754.89M | vs IRWD |
| ARDXArdelyx Inc. | 2.99 | -2.29% | $751.60M | vs IRWD |
| IVAInventiva S.A. American Depository Shares | 3.14 | -8.99% | $750.78M | vs IRWD |
| CRVSCorvus Pharmaceuticals Inc. | 9.67 | -3.40% | $815.69M | vs IRWD |
Indexes, lists and sector
Ironwood Pharmaceuticals stock FAQ
What is Ironwood Pharmaceuticals's stock price today?
IRWD last traded at $4.70 as of Nov 20, 4:00 PM EST, down 0.21% on the day. Prices are delayed at least 15 minutes.
Does Ironwood Pharmaceuticals pay a dividend?
No. Ironwood Pharmaceuticals does not currently pay a regular cash dividend.
What is IRWD's P/E ratio?
IRWD trades at a trailing P/E ratio of 5.22 and a forward P/E of 3.00.
Who is Ironwood Pharmaceuticals's CEO?
Mr. Thomas A. McCourt is the chief executive officer of Ironwood Pharmaceuticals Inc. Class A, which has about 100 employees.
Has IRWD ever split its stock?
Yes. The most recent IRWD stock split was a 1194-for-1000 split on Apr 2, 2019.
What is the IRWD 52-week high?
The 52-week high for IRWD is $5.78 and the 52-week low is $2.95. The stock is currently 18.7% below its high.